Acta Neuropathologica

, Volume 107, Issue 3, pp 216–226 | Cite as

Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs

  • S. Czub
  • M. Czub
  • E. Koutsilieri
  • S. Sopper
  • F. Villinger
  • J. G. Müller
  • C. Stahl-Hennig
  • P. Riederer
  • V. ter Meulen
  • G. Gosztonyi
Regular Paper

Abstract

Drug abuse and human immunodeficiency virus (HIV) infection seem to cause cumulative damage in the central nervous system (CNS). Elevated extracellular dopamine is thought to be a prime mediator of the reinforcing effects of addictive substances. To investigate the possible role of increased dopamine availability in the pathogenesis of HIV dementia, simian immunodeficiency virus (SIV)-infected monkeys were treated with dopaminergic drugs (selegiline or l-DOPA). Both substances increased intracerebral SIV expression, combined with aggravation of infection-related neuropathology and ultrastructural alterations of dendrites in dopaminergic areas (spongiform polioencephalopathy) in asymptomatic animals. Moreover, this treatment resulted in enhanced TNF-α expression in the brains of SIV-infected animals. These findings indicate a synergistic interaction between dopamine and SIV infection on microglia activation, leading to increased viral replication and production of neurotoxic substances. Our results suggest that increased dopamine availability through dopaminergic medication or addictive substances may potentiate HIV dementia.

keywords

Brain HIV Dopamine Selegiline Cytokines 

References

  1. 1.
    Artigas J, Niedobitek F, Grosse G, Heise W, Gosztonyi G (1989) Spongiform encephalopathy in AIDS dementia complex: report of five cases. J Acquir Immune Defic Syndr 2:374–381PubMedGoogle Scholar
  2. 2.
    Bell J, Donaldson Y, Lowrie S, McKenzie C, Elton R, Chiswick A, Brettle R, Ironside J, Simmonds P (1996) Influence of risk group, Zidovudine therapy and immunosuppression on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 10:493–499PubMedGoogle Scholar
  3. 3.
    Benveniste E, Huneycott B, Shrikant P, Ballestas M (1995) Second messenger systems in the regulation of cytokines and adhesion molecules in the central nervous system. Brain Behav Immun 9:304–314CrossRefPubMedGoogle Scholar
  4. 4.
    Berger JR, Nath A (1997) HIV dementia and the basal ganglia. Intervirology 40:122–131Google Scholar
  5. 5.
    Budka H, Wiley C, Kleihues P, Artigas J, Asbury A, Cho E, Cornblath D, DalCanto M, DeGirolami U, Dickson D, Epstein L, Esiri M, Giangaspero F, Gosztonyi G, Gray F, Griffin J, Henin D, Iwasaki Y, Janssen R, Johnson R, Lantos P, Lyman W, McArthur J, Nagashima K, Peress N, Petito C, Price R, Rhodes R, Rosenblum M, Said G, Scaravilli F, Sharer L, Vinters H (1991) HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology—Consensus Report. Brain Pathol 1:143–152PubMedGoogle Scholar
  6. 6.
    Caine SB (1998) Cocaine abuse: hard knocks for the dopamine hypothesis? Nat Neurosci 1:90–92CrossRefPubMedGoogle Scholar
  7. 7.
    Chen G, Tachibana K, Huang DS, Watson RR (1993) Cocaine modulation in vitro of tumor necrosis factor production by macrophages from retrovirally infected mice. Life Sci 52:1641–1647CrossRefPubMedGoogle Scholar
  8. 8.
    Czub M, Czub S, Gosztonyi G, Koutsilieri E, Sopper S, Muller JG, Gerlach M, Riederer P, Meulen V ter (1999) Effects of Selegiline in a retroviral rat model for neurodegenerative disease. J NeuroVirol 5:458–464PubMedGoogle Scholar
  9. 9.
    Czub S, Muller JG, Czub M, Muller-Hermelink HK (1996) Nature and sequence of simian immunodeficiency virus-induced central nervous system lesions: a kinetic study. Acta Neuropathol 92:487–498CrossRefPubMedGoogle Scholar
  10. 10.
    Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, Pedersen V, Gsell W, Heeney JL, Gerlach M, Gosztonyi G, Riederer P, Meulen V ter (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 101:85–91PubMedGoogle Scholar
  11. 11.
    Davies J, Everall I, Weich S, McLaughlin J, Scaravilli F, Lantos P (1997) HIV-associated brain pathology in the United Kingdom: an epidemiological sstudy. AIDS 11:1145–1150CrossRefPubMedGoogle Scholar
  12. 12.
    Demuth M, Czub S, Sauer U, Koutsilieri E, Haaft P, Heeney J, Stahl-Hennig C, Meulen V ter, Sopper S (2000) Relationship between viral load in blood, cerebrospinal fluid, brain tissue and isolated microglia with neurological disease in macaques infected with different strains of SIV. J NeuroVirol 6:187–201PubMedGoogle Scholar
  13. 13.
    DiChiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278PubMedGoogle Scholar
  14. 14.
    Everall I, Luthert P, Lantos P (1993) A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia. J Neuropathol Exp Neurol 52:561–566PubMedGoogle Scholar
  15. 15.
    Gosztonyi G, Schmidt V, Nickel R, Rothschild M, Camach S, Siegel G, Zill E, Pauli G, Schneider V (1993) Neuropathologic analysis of postmortal brain samples of HIV-seropositive and -seronegative i.v. drug addicts. Forensic Sci Int 62:101–105PubMedGoogle Scholar
  16. 16.
    Gotz ME, Freyberger A, Riederer P (1990) Oxidative stress: a role in the pathogenesis of Parkinson’s disease. J Neural Transm Suppl 29:241–249PubMedGoogle Scholar
  17. 17.
    Jellinger KA, Setinek U, Drlicek M, Bohm G, Steurer A, Lintner F (2000) Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol 100:213–220CrossRefPubMedGoogle Scholar
  18. 18.
    Kibayashi K, Mastri A, Hirsch C (1996) Neuropathology of human immunodeficiency virus infection at different disease stages. Hum Pathol 27:637–642Google Scholar
  19. 19.
    Kieburtz K, Epstein L, Gelbard H, Greenamyre T (1991) Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex: therapeutic implications. Arch Neurol 48:1281–1284PubMedGoogle Scholar
  20. 20.
    Koutsilieri E, Gotz ME, Sopper S, Sauer U, Demuth M, Meulen V ter, Riederer P (1997) Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. J NeuroVirol 3:342–349PubMedGoogle Scholar
  21. 21.
    Koutsilieri E, Sopper S, Scheller C, Meulen V ter, Riederer P (2002) Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 109:399–410CrossRefPubMedGoogle Scholar
  22. 22.
    Koutsilieri E, Sopper S, Scheller C, Meulen V ter, Riederer P (2002) Parkinsonism in HIV dementia. J Neural Transm 109:767–775CrossRefPubMedGoogle Scholar
  23. 23.
    Koutsilieri E, Sopper S, Scheller C, Meulen V ter, Riederer P (2002) Dopamine is a pathogenic factor in HIV-induced neuro-AIDS. In: Nagatsu T, Nabeshima R, McCarthy R, Goldstein D (eds) Catecholamine research: from molecular insights to clinical medicine. Kluwer Academic/Plenum, pp 475–478Google Scholar
  24. 24.
    Lipton SA (1997) Neuropathogenesis of acquired immunodeficiency syndrome dementia. Curr Opin Neurol 10:247–253PubMedGoogle Scholar
  25. 25.
    Martinez A, Sell M, Mitrovics T, Stoltenburg-Didinger G, Iglesias-Rozas J, Giraldo-Velásques M, Gosztonyi G, Schneider V, Cervós-Navarro J (1995) The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract 191:427–443PubMedGoogle Scholar
  26. 26.
    Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA (1992) Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 66:285–291PubMedGoogle Scholar
  27. 27.
    Mirsattari S, Power C, Nath A (1998) Parkinsonism with HIV infection. Mov Disord 13:684–689PubMedGoogle Scholar
  28. 28.
    Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335–345CrossRefPubMedGoogle Scholar
  29. 29.
    Poli G, Kinter A, Justement J, Kehrl J, Bressler P, Stanley S, Fauci A (1990) Tumor necrosis factor a functions in autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 87:782–785PubMedGoogle Scholar
  30. 30.
    Raghavan R, Cheney PD, Raymond LA, Joag SV, Stephens EB, Adany I, Pinson DM, Li Z, Marcario JK, Jia F, Wang C, Foresman L, Berman NE, Narayan O (1999) Morphological correlates of neurological dysfunction in macaques infected with neurovirulent simian immunodeficiency virus. Neuropathol Appl Neurobiol 25:285–294CrossRefPubMedGoogle Scholar
  31. 31.
    Sauermann U, Stahl-Hennig C, Stolte N, Muhl T, Krawczak M, Spring M, Fuchs D, Kaup FJ, Hunsmann G, Sopper S (2000) Homozygosity for a conserved MHC class II DQ-DRB haplotype is associated with rapid disease progression in simian immunodeficiency virus-infected macaques: results from a prospective study. J Infect Dis 182:716–724PubMedGoogle Scholar
  32. 32.
    Sawaya B, Rohr O, Aunis D, Schaeffer E (1996) Chicken ovalbumin upstream promoter transcription factor, a transcriptional activator of HIV-1 gene expression in human brain cells. J Biol Chem 271:23572–23576CrossRefPubMedGoogle Scholar
  33. 33.
    Scheller C, Sopper S, Jassoy C, Meulen V ter, Riederer P, Koutsilieri E (2000) Dopamine activates HIV in chronically infected T lymphoblasts. J Neural Transm 107:1483–1489CrossRefPubMedGoogle Scholar
  34. 34.
    Shapshak P, Crandall K, Xin K, Goodkin K, Fujimura R, Bradley W, McCoy C, Nagano I, Yoshioka M, Petito C, Sun N, Srivastava A, Weatherby N, Stewart R, Delgado S, Matthews A, Douyon R, Okuda K, Yang J, Zhangl B, Cao X, Shatkovsky S, Fernandez J, Shah S, Perper J (1996) HIV-1 neuropathogenesis and abused drugs: current reviews, problems, and solutions. Adv Exp Med Biol 402:171–186PubMedGoogle Scholar
  35. 35.
    Smiley JF, Levey AI, Ciliax BJ, Goldman-Rakic PS (1994) D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 91:5720–5724PubMedGoogle Scholar
  36. 36.
    Solitare GB (1972) Neuropathologic aspects of drug dependency (narcotic addiction). Hum Pathol 3:85–89PubMedGoogle Scholar
  37. 37.
    Sopper S, Sauer U, Hemm S, Demuth M, Müller J, Stahl-Hennig C, Hunsmann G, Meulen V ter, Dörries R (1998) Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques. J Virol 72:9940–9947PubMedGoogle Scholar
  38. 38.
    Sopper S, Sauer U, Muller JG, Stahl-Hennig C, Meulen V ter (2000) Early activation and proliferation of T cells in simian immunodeficiency virus-infected rhesus monkeys. AIDS Res Hum Retroviruses 16:689–697CrossRefPubMedGoogle Scholar
  39. 39.
    Sopper S, Koutsilieri E, Scheller C, Czub S, Riederer P, Meulen V ter (2002) Macaque animal model for HIV-induced neurological disease. J Neural Transm 109:747–766CrossRefPubMedGoogle Scholar
  40. 40.
    Stahl-Hennig C, Voss G, Dittmer U, Coulibaly C, Petry H, Makoschey B, Cranage M, Aubertin A, Luke W, Hunsmann G (1993) Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS 7:787–795PubMedGoogle Scholar
  41. 41.
    Szabo J, Cowan WM (1984) A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J Comp Neurol 222:265–300PubMedGoogle Scholar
  42. 42.
    Tan SV, Guiloff RJ (1998) Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 65:23–28PubMedGoogle Scholar
  43. 43.
    Tatton WG, Chalmers-Redman RM (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171–183PubMedGoogle Scholar
  44. 44.
    Tipton K, Singer T (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191–1207PubMedGoogle Scholar
  45. 45.
    Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE (1999) Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathol Appl Neurobiol 25:369–379CrossRefPubMedGoogle Scholar
  46. 46.
    Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA (1995) Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol 155:3946–3954PubMedGoogle Scholar
  47. 47.
    Wiley C, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Hermann S, Dailey P, Achim C (1998) Distribution of brain HIV load in AIDS. Brain Pathol 8:277–284PubMedGoogle Scholar
  48. 48.
    Wiley CA, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991) Neocortical damage during HIV infection. Ann Neurol 29:651–657Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • S. Czub
    • 1
  • M. Czub
    • 2
  • E. Koutsilieri
    • 3
  • S. Sopper
    • 2
  • F. Villinger
    • 4
  • J. G. Müller
    • 1
  • C. Stahl-Hennig
    • 5
  • P. Riederer
    • 3
  • V. ter Meulen
    • 2
  • G. Gosztonyi
    • 6
  1. 1.Pathological InstituteUniversity WürzburgWürzburgGermany
  2. 2.Institute of Virology and ImmunobiologyUniversity WürzburgWürzburgGermany
  3. 3.Clinical Neurochemistry, Clinic and Polyclinic of Psychiatry and PsychotherapyUniversity WürzburgWürzburgGermany
  4. 4.Emory University School of MedicineDepartments of Pathology and Laboratory MedicineAtlantaUSA
  5. 5.Department of VirologyGerman Primate CenterGöttingenGermany
  6. 6.Department of NeuropathologyUniversity Clinics Benjamin FranklinBerlinGermany

Personalised recommendations